|Indena is the leading company dedicated to the identification, development and production of high quality active principles derived from plants, for use in the pharmaceutical, health food and personal care industries. Backed up by over 90 years of botanical experience, the company holds more than 120 primary patents, has published more than 700 scientific studies and co-operates with the world’s most prestigious universities and private research institutions. Indena employs about 800 staff, investing around 10% of its annual turnover in research. Headquartered in Milan, Indena has 5 production sites and 5 international branches throughout the world and manages sales in more than 70 countries. The company's experts communicate and interact constantly with the major international regulatory authorities such as WHO, EMA, and ESCOP, and cooperate on the update of all the main pharmacopoeias.
The key to Indena’s success is its research, covering: the screening of medicinal plants for pharmacological benefits; the identification of new active principles; the development of cutting-edge extraction and purification systems for industrial applications.
A key strategic research objective is the development of new active principles for pharmaceutical applications. This also forms an indispensable base for the health-food and personal care industries.
The pharmaceutical side of the company is focused mainly on anti-cancer drugs, which are produced to US-FDA, ICH and EU standards at Indena’s Highly Potent Contract Manufacturing site in Settala (Italy), that meets US-FDA, ICH and EU requirements. This facility incorporates appropriate room pressurization, airlocks, ventilation and isolators to properly handle highly potent solids and liquids up to 0.8 µg/m3 OEL (Class 4).
Indena’s drug discovery strategy is to develop new chemical entities up to “Phase I/II” of clinical studies, and then license them to pharmaceutical companies.
Indena has traditionally provided Contract Manufacturing Services such as the extraction, isolation, purification and synthetic modifications of natural derivatives by means of a full range of manufacturing capabilities on a wide range of scales in state-of-the-art facilities in Europe.
A new multipurpose pilot plant for semi-synthesis, suitable for the extraction of toxic plants and equipped with chromatographic purification columns, as well as a kilo-lab for very high toxic products (OEL 20 – 50 ng/m3) has been completed. This will widen Indena’s capability and services in Custom Synthesis. New projects are already on-going from early-stage to large scale industrial production.
Indena’s partners range from small start-ups to large multinational pharmaceutical companies and they see Indena as a branch of their own R&D and Manufacturing resources with full confidence guaranteed by the inspection history and strength of the Company.